A Multi-Center, Dose Finding, Open Label, Phase 1 Study of RX-5902 in Subjects With Advanced or Metastatic Solid Tumors

Trial Profile

A Multi-Center, Dose Finding, Open Label, Phase 1 Study of RX-5902 in Subjects With Advanced or Metastatic Solid Tumors

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 14 Aug 2018

At a glance

  • Drugs RX 5902 (Primary)
  • Indications Advanced breast cancer; Ovarian cancer; Solid tumours
  • Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
  • Sponsors Rexahn Pharmaceuticals
  • Most Recent Events

    • 06 Aug 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Oct 2018.
    • 05 Jun 2018 Results (n=11, data cut off: Feb 2018) presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 04 Jun 2018 Interim results (n=10) from triple negative breast cancer patients in phase IIa portion of this trial presented in a Rexahn Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top